We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Seegene's Syndromic Test Detects 21 Targets for 19 Respiratory Viruses in Single Sample, Including COVID-19 and Flu

By LabMedica International staff writers
Posted on 07 Apr 2022
Print article
Image: Allplex RV Master Assay has received Australian TGA approval and European CE-IVD mark (Photo courtesy of Seegene, Inc.)
Image: Allplex RV Master Assay has received Australian TGA approval and European CE-IVD mark (Photo courtesy of Seegene, Inc.)

The world has turned its focus to living with COVID-19 endemically and relaxed social distancing and mask restrictions have created an environment for various respiratory viruses to circulate with ease. Symptoms of COVID-19, such as coughing and fever, can also be a sign of other respiratory infections. A recent study showed that patients who contracted both COVID-19 and flu had more than double the risk of death, while the need for invasive medical ventilation jumped by four-fold. This makes testing critical for proper care as treatments can vary by infection type and to reduce the potential of co-infection. Now, a new test detects 21 targets for 19 respiratory viruses in single tube, including COVID-19 and flu.

Seegene, Inc.’s (Seoul, Korea) Allplex RV Master Assay can distinguish 21 targets for 19 different respiratory viruses, including COVID-19, flu, and common colds. Specifically, the assay can identify three genes of COVID-19, Flu A, Flu B, metapneumovirus, two types of respiratory syncytial virus, four types of parainfluenza virus, six types of adenovirus and three types of human rhinovirus. The syndromic test allows medical specialists to swiftly find out which viruses are making the patient sick with a single sample.

Seegene's independent clinical test recently conducted in Europe using the Allplex RV Master Assay on 1,928 people found that 16.5% (318 people) tested positive for respiratory viruses, excluding COVID-19. Of that figure, 6.9% (22 people) had contracted two or more viruses. The Allplex RV Master Assay has been designed in consideration of countries shifting policies to get everyday life back to normal. The Allplex RV Master Assay has received approval from Australia's Therapeutic Goods Administration and also achieved the European CE-IVD marking.

"Allplex RV Master Assay can detect respiratory viruses that can occur all-year round to simplify the diagnostic of the 'new normal' respiratory virus composition," said Dr. Tove Havnhøj Frandsen of Hospital of Southern Jutland/RenTov Consult, who led Seegene's clinical test in Europe. "The assay is expected to be well-utilized as winter approaches in Australia and South America and as the world turns to live with COVID-19 endemically."

Related Links:
Seegene, Inc.

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.